Virtu KCG Holdings LLC raised its position in Kindred Biosciences, Inc. (NASDAQ:KIN) by 41.7% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 15,285 shares of the biopharmaceutical company’s stock after buying an additional 4,495 shares during the period. Virtu KCG Holdings LLC owned about 0.07% of Kindred Biosciences worth $131,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Goldman Sachs Group Inc. boosted its position in Kindred Biosciences by 28.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 22,336 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 4,954 shares during the last quarter. Nationwide Fund Advisors bought a new position in Kindred Biosciences in the 2nd quarter valued at $100,000. JPMorgan Chase & Co. bought a new position in Kindred Biosciences in the 2nd quarter valued at $119,000. Trexquant Investment LP bought a new position in Kindred Biosciences in the 2nd quarter valued at $120,000. Finally, State of Wisconsin Investment Board bought a new position in Kindred Biosciences in the 2nd quarter valued at $129,000. Hedge funds and other institutional investors own 60.37% of the company’s stock.

Separately, Zacks Investment Research upgraded Kindred Biosciences from a “hold” rating to a “buy” rating and set a $8.25 price objective on the stock in a research report on Thursday, August 3rd. Three research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $9.19.

ILLEGAL ACTIVITY WARNING: “Virtu KCG Holdings LLC Purchases 4,495 Shares of Kindred Biosciences, Inc. (KIN)” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at

Kindred Biosciences (NASDAQ:KIN) last issued its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.04.

Kindred Biosciences Profile

Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.

Want to see what other hedge funds are holding KIN? Visit to get the latest 13F filings and insider trades for Kindred Biosciences, Inc. (NASDAQ:KIN).

Institutional Ownership by Quarter for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.